Anesthesia and Resuscitation Unit, Cecina Hospital - Azienda USL Toscana Nord Ovest
Cecina, Italy
NCT Number: NCT07648563
The goal of this clinical trial is to evaluate if Forest therapy can reduce pain levels and improve the quality of life related to the level of pain perceived in fibromyalgia patients.
The main question it aims to answer is:
Does frequenting certified forest environments, according to the principles and methods of Forest Therapy, produce positive effects on chronic pain and the consumption of painkillers? The study is part of the "Forest Therapy Project as a Broad-Spectrum Tool for Patients Affected by Fibromyalgia" funded by the Tuscany Region as part of the Complementary Medicine program for the three-year period 2025-2027. The project will be carried out thanks to the collaboration with the National Research Council - Institute for BioEconomy (CNR-IBE)
Trial opening soon.
Get Notified18 year and older
All sexes
Interventional
Not applicable
Cecina, Italy
Participants will be divided into two groups. One group, called the "intervention group," will participate in experimental Forest Therapy sessions at an easily accessible forest site. Another group, called the "control group," will not be required to make any changes to their usual habits or activities.
The Forest Therapy sessions consist of short, slow walks, intentionally without significant physical exertion, along safe and easy paths. Led by clinical professionals such as doctors, psychologists, or psychotherapists from the Anesthesia and Intensive Care Unit of Cecina, the sessions include frequent breaks and encourage concentration on the sensory connection with the forest environment.
The study is randomized, so assignment to one of the two treatment groups above will follow a pre-defined random criterion.
During the study, all patients will follow standard therapeutic treatments specific to their condition.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Each session of Forest therapy will be organized as follows: 1. Gathering at the meeting point with the participants, doctor, psychologist, and staff.
Slow walking - 5 minutes. Visual perception - 15 minutes. Slow walking - 5 minutes. Auditory perception - 15 minutes. Slow walking - 5 minutes. Tactile perception - 15 minutes. Slow walking - 5 minutes. Olfactory perception - 15 minutes. Slow walking - 5 minutes. Perceptual and movement activity chosen by the participant - 20 minutes. 5. Walk back to the starting/ending point - 20 minutes. STAI-S and POMS test and final physiological measurements - 30 minutes
Time frame: Up to the last follow-up 3 months after the end of the therapy
Level of perceived pain assessed using the Visual Analog Scale (VAS), a validated gold standard for fibromyalgia and allowing for direct and comparable measurement. The Visual Analogue Scale is the most widely used method in medicine to measure the intensity of pain subjectively perceived by the patient. It is usually represented as a continuous line 10 centimetres long, the ends of which indicate two opposite conditions: left end (0): no pain ; right end (10): the worst pain imaginable. The patient fills in the instrument by making a mark on the line at the point corresponding to the pain he or she feels. The operator then measures the distance in millimetres (from 0 to 100) to obtain the score. Interpretation of the Scores (cut-off): based on various clinical studies, the values of the scale are generally divided into 4 ranges: 0 - 4 mm: no pain ; 5 - 44 mm: mild pain ; 45 - 74 mm: Moderate pain; 75 - 100 mm: Severe pain.
Time frame: Up to the last follow-up 3 months after the end of the therapy
The Revised Fibromyalgia Impact Questionnaire (FIQR) is a self-assessment questionnaire used to measure the impact of fibromyalgia on quality of life.
The FIQR has 21 individual questions. All questions are based on an 11-point numeric rating scale of 0 to 10, with 10 being 'worst'. All questions are framed in the context of the past 7 days. The FIQR is divided into 3 linked sets of domains (symptoms, function and overall impact of the disease) and the final score (0-100) is obtained by summing the values of the 3 domains. Four severity categories and their corresponding cutoffs have been identified: remission if final score ≤30, mild if final score >30 and ≤45, moderate if final score >46 and ≤65, severe if final score >65. The study will evaluate the change in the score of the FIQR in the 2 arms.
Time frame: Up to the last the follow-up 3 months after the end of the therapy
The Widespread Pain Index (WPI) is one of two key parameters used for the assessment and diagnosis of fibromyalgia. It measures the extent of body pain . The questionnaire asks the patient to indicate in which specific areas of the body they have felt pain during the last week. The list consists of 19 body areas. One point is assigned for each area where pain is present. The total score therefore ranges from 0 (no area) to 19 (all the body).
Time frame: From the beginning of the forest therapy session to the end of the session
The State-Trait Anxiety Inventory (STAI) is a standardized psychometric scale for measuring anxiety. It is divided into two parts: 20 questions to assess trait anxiety (STAI-T) and 20 questions to assess state anxiety (STAI-S). The STAI is a 60-point scale (from 20 to 80) where 20 indicates the lowest level of anxiety and 80 the highest possible score.
Time frame: From the beginning of the forest therapy session to the end of the session
The Profile of Mood States" (POMS) questionnaire is a psychological and psychiatric questionnaire used to assess mood and emotional states. It is used in the management of fibromyalgia to quantify the psychological impact (e.g., anxiety, depression, fatigue) and stress related to chronic pain. The test consists of a list of adjectives (typically 65 in the standard version) that describe feelings and emotions experienced "including today." The patient rates each adjective on a scale from 0 (not at all) to 4 (extremely). The questionnaire measures 6 mood dimensions: Tension-Anxiety (e.g., tense, anxious, nervous); Depression-Disappointment (e.g., unhappy, sad, hopeless); Truth-Hostility (e.g., angry, resentful, offended); Vigor-Activity (e.g., active, energetic, lively); Fatigue-Inertia (e.g., tired, exhausted, listless); Confusion-Disconcertment (e.g., confused, disoriented, forgetful).
Time frame: Up to the last follow-up 3 months after the end of the therapy
Changes in systolic and diastolic blood pressure in mmHg
Time frame: Up to the last follow-up 3 months after the end of the therapy
Heart Rate in ms
Time frame: Up to the last follow-up at 3 months after the end of the therapy
Heart Rate Variability Variation in ms
Time frame: Up to the last follow-up at 3 months after the end of the therapy
Possible change in pain medication use at the end of the study (intervention groups vs. control groups).
Time frame: From the beginning of the forest therapy session to the end of the session
Dependence of the variation of the aforementioned scores and parameters on environmental variables (meteorological comfort, volatile organic pollutants and biogenic volatile organic compounds), assessed during the forestry therapy sessions for the intervention groups only
Time frame: Up to the last follow-up 3 months after the end of the therapy
The Symptom Severity Scale (SSS) is one of the two main measures used to evaluate and diagnose fibromyalgia. It measures the overall severity of symptoms. It is commonly calculated in conjunction with the WPI scale. The SSS scale assigns a score from 0 to 12, adding the two values: severity of the 3 main syntoms e general somatic syntoms:
Contact information is provided by the study sponsor or research team.
Azienda USL Toscana Nord Ovest
Other
A Monocentric, Randomized, Controlled, No-profit, Interventional Study on the Effects of Forest Therapy in Patients With Fibromyalgia
Acronym: ForCare
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07663604
Fybromyalgia, Neurologic Manifestations
Denizli, Şirnak, Turkey (Türkiye)
View Trial DetailsNCT07605143
Fybromyalgia
Concepción, Biobio, Chile
View Trial DetailsNCT07718984
Fibromyalgia, Fibromyalgia (FM)
Decatur, Georgia, United States
View Trial DetailsNCT07403929
Chronic Pain, Fibromyalgia
Istanbul, Turkey (Türkiye)
View Trial Details